Clinical Trial ProgressJasper Therapeutics announced significant progress across its briquilimab programs, showing continued advancement in their clinical trials.
Efficacy And SafetyPrevious data demonstrated continued tolerability and a favorable safety profile for briquilimab, supporting further clinical study plans.
Market OpportunitiesBEACON now includes omalizumab-naive patients, which could grow the addressable population for JSPR.